Maravai LifeSciences vs Personalis
Maravai LifeSciences reported revenue of $186 million in fiscal 2025, 2.7 times Personalis' $70 million in fiscal 2025. Maravai LifeSciences' revenue fell 28.3% in its latest year, and Personalis' fell 17.7%. Maravai LifeSciences had an operating margin of -115.9%, against -126.4% at Personalis. Free cash flow was −$71 million at Maravai LifeSciences and −$79 million at Personalis.
Side by side
| Maravai LifeSciences | Personalis | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $186M | $70M |
| Revenue growth | −28.3% | −17.7% |
| Revenue growth a year, last 5 years | −8.2% | −2.4% |
| Gross margin | 18.3% | 22.6% |
| Operating margin | −115.9% | −126.4% |
| Net margin | −70.4% | −116.7% |
| Free cash flow | −$71M | −$79M |
| Free cash flow margin | −38.1% | −114.1% |
| Return on capital | −32.0% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.7% | 50.6% |
| Last close | $7.54 | $15.71 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Maravai LifeSciencesPersonalis
Operating margin
Percent of revenue
Maravai LifeSciencesPersonalis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Maravai LifeSciencesPersonalis
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Maravai LifeSciences and Personalis pages.